EUVIMEDEUVIMED entdecken
Crossref

Higher Adalimumab Concentration Is Associated With Complete Fistula Healing in Patients With Perianal Fistulizing Crohn’s Disease

Konstantinos Papamichael, Andrea Centritto, Lucas Guillo, Jessica Hier, Zachary Sherman, Adam S Cheifetz, International Consortium of Therapeutic Drug Monitoring (Spectrum)

Clinical Gastroenterology and Hepatology · 2024-10 · 22 (10) · 2134-2136.e2

DOI: 10.1016/j.cgh.2024.04.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024-10. Verfasst von Konstantinos Papamichael und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachus…. Hauptthemen laut MEDLINE: Crohn Disease, Adalimumab, Rectal Fistula. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Perianal fistulas can develop in around 30% of patients with Crohn's disease (CD) and are associated with impaired quality of life and worse outcomes including increased rates of hospitalizations and surgeries.1 The cornerstone of pharmacologic treatment for perianal fistulizing CD is anti-tumor necrosis factor therapy, mainly infliximab and adalimumab (ADM).2 Therapeutic drug monitoring (TDM) can be used to identify potential pharmacokinetic and pharmacodynamic issues and avoid or manage unwanted outcomes, such as primary nonresponse and secondary loss of response.3 There are several exposure-response relationship data demonstrating a positive correlation between serum infliximab concentrations and favorable objective therapeutic outcomes in patients with perianal fistulizing CD.4 Nevertheless, there are only limited data, which is mostly from small retrospective studies regarding the association of ADM concentration and outcomes in patients with perianal fistulizing CD.4-8 Furthermore, the optimal ADM concentration for fistula healing still remains to be elucidated. This is clinically important because drug concentration cutoffs are used in reactive and proactive TDM algorithms to define therapeutic drug concentrations. This study investigates the association of maintenance ADM concentrations with complete fistula healing (CFH) and identifies an optimal ADM concentration threshold for CFH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseAdalimumabRectal FistulaHumansMaleFemaleAdultRetrospective StudiesTreatment OutcomeYoung AdultMiddle AgedDrug MonitoringWound HealingAnti-Inflammatory Agents

Substanzen

AdalimumabAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Electronic address: kpapamic@bidmc.harvard.edu.
  • IBD Center, Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
  • Department of Gastroenterology, Nancy University Hospital, Nancy, France; INSERM U1256 NGERE, Lorraine University, Nancy, France; Department of Gastroenterology, University Hospital of Marseille Nord, University of Aix-…
  • Division of Gastroenterology, Department of Medicine, McGill University Health Center, Montreal, Quebec, Canada.
  • Division of Gastroenterology, Department of Medicine, Weill Cornell Medical College, New York, New York; Gastro Florida, Tampa, Florida.
  • Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

Zitieren

APA

Papamichael, K., Centritto, A., Guillo, L., Hier, J., Sherman, Z., Cheifetz, A. S., & International Consortium of Therapeutic Drug Monitoring (Spectrum) (2024). Higher Adalimumab Concentration Is Associated With Complete Fistula Healing in Patients With Perianal Fistulizing Crohn’s Disease. Clinical Gastroenterology and Hepatology, 22(10), 2134-2136.e2. https://doi.org/10.1016/j.cgh.2024.04.005

Vancouver

Papamichael K, Centritto A, Guillo L, Hier J, Sherman Z, Cheifetz AS, et al. Higher Adalimumab Concentration Is Associated With Complete Fistula Healing in Patients With Perianal Fistulizing Crohn’s Disease. Clinical Gastroenterology and Hepatology. 2024;22(10):2134-2136.e2. doi:10.1016/j.cgh.2024.04.005

BibTeX
@article{Papamichael2024,
  author = {Papamichael, Konstantinos and Centritto, Andrea and Guillo, Lucas and Hier, Jessica and Sherman, Zachary and Cheifetz, Adam S and International Consortium of Therapeutic Drug Monitoring (Spectrum), International Consortium of Therapeutic Drug Monitoring (Spectrum)},
  title = {Higher Adalimumab Concentration Is Associated With Complete Fistula Healing in Patients With Perianal Fistulizing Crohn’s Disease},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2024},
  volume = {22},
  number = {10},
  pages = {2134--2136.e2},
  doi = {10.1016/j.cgh.2024.04.005}
}
Kostenlos starten →